Clinical trial NCT00630799: Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients
Official title: Efficacy and Safety of a New Leuprolide Acetate 17 mg Depot Formulation, GP-Pharm S.A., When Given as Palliative Treatment to Prostate Cancer Patients
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Prostate Cancer
Keywords: prostate
cancer
Lead sponsor: GP-Pharm
Sponsor class: INDUSTRY
First posted: 2008-03-07
Enrollment: 20
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: This is a multi-center, open-label study of 2 doses of leuprolide acetate 17 mg depot, administered three months apart, in subjects with prostate cancer who might benefit from medical androgen deprivation therapy


Eligibility criteria: Inclusion Criteria:

* Males 18 years of age, with histologically proven carcinoma of prostate, who might benefit from medical androgen deprivation therapy;
* life expectancy of at least 1 year;
* WHO/ECOG performance status of 0, 1, or 2;
* adequate renal function at screening as defined by serum creatinine \<= 1.6 times the upper limit of normal (ULN) for the clinical laboratory;
* adequate and stable hepatic function as defined by bilirubin \<= 1.5 times the ULN and transaminases (i.e. SGOT, SGPT) \<= 2.5 times the ULN for the clinical laboratory at screening;
* ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the Investigator and to comply with the requirements of the entire study;
* signed written informed consent prior to inclusion in the study.

Exclusion Criteria:

* Evidence of brain metastases, in the opinion of the Investigator, taking into account medical history, clinical observations and symptoms;
* evidence of spinal cord compression, in the opinion of the Investigator, taking into account medical history, clinical observations and symptoms;
* evidence of severe urinary tract obstruction with threatening urinary retention, in the opinion of the Investigator, taking into account medical history, clinical observations and symptoms;
* presence of any tumor in the immediate vicinity which could cause cord compression, in the opinion of the Investigator, taking into account medical history and clinical observations;
* excruciating, severe pain from extensive osseous deposits, in the opinion of the Investigator, taking into account medical history, clinical observations and symptoms;
* testosterone levels \<= 1.5 ng/mL at screening, locally determined at the laboratory of each clinical site;
* previous cancer systemic therapy such as chemotherapy, immunotherapy (e.g. antibody therapies, tumor-vaccines), biological response modifiers (e.g. cytokines) within 3 months of baseline;
* previous hormonal therapy for treatment of prostate cancer, such as LHRH analogues (e.g. Lupron®, Zoladex®, etc.) (no wash-out allowed);
* previous treatment with AR-receptor blockers, such as Casodex®, Fugerel®, Megace®, Androcur®(no wash-out allowed);
* previous orchiectomy, adrenalectomy or hypophysectomy;
* previous prostatic surgery (e.g. radical prostatectomy, transurethral resection of the prostate (TUR-P) within 2 weeks prior to or after baseline;
* previous local therapy to the primary tumor with a curative attempt other than surgery (external beam radiotherapy, brachytherapy, thermotherapy, cryotherapy) within 2 weeks prior to or after baseline;
* any investigational drug within 5 half-lives of its physiological action or 3 months, whichever is longer, before baseline;
* administration of 5-α-reductase inhibitors (Proscar®, Avodart®, Propecia®) within 3 months before baseline;
* over-the-counter (OTC) or alternative medical therapies which have an estrogenic or anti-androgenic effect (i.e., PC-SPES, saw palmetto, Glycyrrhiza®, Urinozinc®, DHEA) within the 3 months before baseline;
* hematological parameters (RBC, total and differential WBC count, platelet count, hemoglobin, hematocrit) outside 20% of the upper or lower limits of normal (ULN, LLN) for the clinical laboratory at screening;
* co-existent malignancy, according to the Investigator's opinion;
* uncontrolled congestive heart failure, myocardial infarction or a coronary vascular procedure (e.g. balloon angioplasty, coronary artery bypass graft) or significant symptomatic cardiovascular disease(s) within 6 months before baseline; resting uncontrolled hypertension: \>=160/100 mmHg) or symptomatic hypotension within 3 months before baseline;
* venous thrombosis within 6 months of baseline;
* uncontrolled diabetes (patients with uncontrolled diabetes need to compensate the metabolic disorder before treatment with LH-RH analogues);
* history of drug and/or alcohol abuse within 6 months of baseline;
* serious concomitant illness(es) or disease(s) (e.g., hematological, renal, hepatic, respiratory, endocrine, psychiatric) that may interfere with, or put patients at additional risk for, their ability to receive the treatment outlined in the protocol;
* patients on anticoagulative therapy including warfarin (Coumadin®) and heparin. Those patients on low dose low molecular weight heparin may be enrolled in the study;
* Abnormal coagulation studies (PT/PTT) at baseline.
* blood donations/losses within 2 months of baseline, apart from previous prostatic surgery patients (see exclusion 10);
* known hypersensitivity to GnRH, GnRH agonist, including any LHRH analogues, or any excipients of the study formulation;
* history of the following prior to the study:

  * immunization (within 4 weeks of baseline);
  * flu shots (within 1 week of baseline or 1 week prior to and after study drug administration);
  * anaphylaxis;
  * skin disease which would interfere with injection site evaluation;
  * dermatographism will be documented at screening and followed up while on treatment.

Primary outcomes:
measure: Percent of successful patients achieving chemical castration
timeFrame: Days 28, 84, and 168
Secondary outcomes:
measure: WHO/ECOG performance status
timeFrame: Days 14, 28, 56, 84, 112, and 168
measure: Serum LH concentration (mIU/mL)
timeFrame: Days 2, 14, 28, 56, 84, 86, 112, and 168
measure: Serum FSH concentration (mIU/mL)
timeFrame: Days 2, 14, 28, 56, 84, 86, 112, and 168
measure: Serum PSA concentration (ng/mL)
timeFrame: Days 2, 14, 28, 56, 84, 86, 112, and 168
measure: Frequency of bone pain
timeFrame: Days 2, 14, 28, 56, 54, 84, 86, 112, and 168
measure: plasma testosterone concentration (ng/mL) in PK population
timeFrame: week 4 and week 12
measure: Occurrence of hot flushes
timeFrame: Days 0, 2, 14, 28, 56, 84, 86, 112, and 168
measure: Plasma leuprolide concentrations (pg/mL) in PK population
timeFrame: Days 2, 14, 28, 56, 84, 86, 112, and 168
measure: Frequency of urinary symptoms
timeFrame: Days 2, 14, 28, 56, 54, 84, 86, 112, and 168
measure: Frequency of urinary pain
timeFrame: Days 2, 14, 28, 56, 54, 84, 86, 112, and 168
Other outcomes:
Locations:
city: New Port Richey
country: United States
facility: Advanced Research Institute
state: Florida
city: Lawrenceville
country: United States
facility: Lawrenceville Urology
state: New Jersey
city: Poughkeepsie
country: United States
facility: Hudson Valley Urology
state: New York
city: Winston-Salem
country: United States
facility: Piedmont Medical Research
state: North Carolina
city: Bryn Mawr
country: United States
facility: Center for Urologic Care
state: Pennsylvania
city: Myrtle Beach
country: United States
facility: Carolina Urologic Research Center
state: South Carolina
city: Nashville
country: United States
facility: Urology Associates
state: Tennessee
city: San Antonio
country: United States
facility: Urology San Antonio Research, PA
state: Texas
Study officials:
References: